TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Purple Biotech Ltd.
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress

Purple Biotech will present new preclinical data on its CAPTN-3 platform of conditionally activated tri-specific antibodies at the ESMO Immuno-Oncology 2025 Congress, showcasing potential advances in cancer treatment targeting tumor immune evasion and drug resistance.

Insights
AVGO   neutral

Mentioned as a semiconductor company, no specific performance details provided


PPBT   positive

Company is presenting promising preclinical data demonstrating novel technology with potential to overcome tumor immune evasion, showing innovative research and development progress